GLP-1 drugs show lower obesity-related cancer risk than insulin, but not all diabetes treatments
Years of research point to obesity and type 2 diabetes raising the risk of developing several types of cancer. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a recent medical breakthrough, were originally developed for blood sugar control or diabetes management and also work overtime promoting weight loss. Scientists are curious to explore whether there are any links between these drugs…
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
EEG analysis estimates depressive symptom severity in adults not receiving psychiatric treatment
United Kingdom
-
Norovirus No. 1 cause of cruise ship outbreaks for past 30 years, but other pathogens gaining
United Kingdom
-
Stopping Ozempic may be bad for your health
United Kingdom
-
Resistance training key to maintaining muscle function during GLP-1 weight loss, study shows
United Kingdom
-
Uncovering the regulators of inflammatory responses in macrophages
United Kingdom
-
Almost one in four Americans believe misinformation about the cause of autism
United Kingdom
-
Night owls who eat late may face higher health risks
United Kingdom
-
Older female influencers challenging stereotypes around aging
United Kingdom